TORONTO, ON–(Marketwired – May 20, 2016) –
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES
PharmaCan Capital Corp. (“PharmaCan” or the “Company”) (TSX VENTURE: MJN) — Lorne Gertner has announced his resignation as a director of PharmaCan effective May 19, 2016 so that he may focus on other opportunities. PharmaCan is pleased to have had the opportunity to benefit from Mr. Gertner’s participation on the board.
The board of directors of the Company consists of Michael Gorenstein, Michael Krestell (independent) and Alan Friedman (independent).
About PharmaCan Capital Corp.
PharmaCan is a company in the business of investing in companies licensed to produce medical marihuana pursuant to Canada’s MMPR.
Forward Looking Statements
This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, including the Company’s ability to implement its business development strategy. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. All forward-looking information contained in this news release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, PharmaCan disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information was obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investor & Media Relations
Michael Krestell
PharmaCan Capital Corp.
Phone: (416) 603-7381 EXT #236
Email: [email protected]
